May 2026 Research Update

This month added more clarity about treatment research without yet answering the biggest patient question: how much different therapies change day-to-day health and long-term outcomes. One analysis showed that vutrisiran produces steady lowering of transthyretin (TTR) in the blood across both nerve and heart forms of ATTR, which supports it as a reliably delivered gene-silencing approach. Another report described the starting point for a major eplontersen trial in ATTR cardiomyopathy, showing participants look similar to people in prior ATTR heart studies but in a more contemporary care setting. [1] [2]

For vutrisiran, researchers looked at how much TTR levels drop at peak and just before the next dose in two HELIOS trials, one focused on ATTRv with nerve problems and one on ATTR cardiomyopathy. They reported rapid and sustained TTR lowering over time, with model predictions suggesting this pattern stays consistent through longer follow-up and across subgroups. This matters because it strengthens the idea that the medication is doing its intended biological job in different types of ATTR, even though this analysis did not directly report symptom or survival benefits. [1]

For eplontersen, the new information was about who is enrolled at baseline in the ongoing CARDIO-TTRansform trial, rather than results of the treatment itself. The report described 1,432 people with ATTR cardiomyopathy, mostly with mild to moderate heart failure symptoms, and many already receiving other ATTR-related therapies at the time they entered the study. This helps patients understand that upcoming trial results will apply to a broad, real-world-like group, but it does not yet tell whether eplontersen improves outcomes. [2]

For patients and caregivers, this month mostly improves the "roadmap" of treatment research rather than changing what is known about benefits. The vutrisiran analysis supports that TTR lowering in blood is consistent over time and across ATTR types, which is useful because it confirms the medicine is having a predictable biological effect. The eplontersen report helps clarify who is being studied in a major heart trial, which matters for how future results may apply to people with ATTR-CM. What remains unknown from these papers is how much these approaches change symptoms, daily function, hospitalizations, or survival, because those outcomes were not reported here. [1] [2]

These studies painted a consistent picture that ATTRv amyloidosis often develops in a varied, step-by-step way that can delay diagnosis, and that living longer with the condition can bring new organ issues. Across countries and care settings, people were commonly classified as having mainly nerve involvement or a mixed nerve-and-heart pattern, and the path to diagnosis often included many healthcare visits before ATTRv was recognized. One smaller cohort also highlighted that, over time, eye problems can become a more prominent issue for long-term survivors. [3] [4]

In the multicountry OverTTuRe study, many patients had substantial healthcare use before diagnosis, and the time from first non-heart symptoms to diagnosis ranged from under a year to several years depending on country and phenotype. Outcomes after diagnosis also varied, with higher mortality reported in people categorized as having mixed involvement compared with nerve-only patterns in several settings. The same analysis reported that many patients did not receive disease-modifying ATTR therapies in the databases studied, with large differences between countries. [3]

In a 25-year Japanese cohort from a non-endemic region, new diagnoses increased over time but diagnostic delays still occurred. The group described a shift in practice from patisiran to vutrisiran, where switching lowered serum TTR levels in the short term, while heart-related blood tests and ultrasound measures did not show clear short-term change. The study also reported that ocular (eye) manifestations became more common with longer disease duration, highlighting that the set of symptoms can evolve over many years. [4]

For patients, these results help put individual experiences into context: ATTRv can start with non-specific nerve or body symptoms, and it may take time before the condition is identified. The findings also help clarify that problems outside the nerves and heart, such as eye involvement, may become more noticeable in people living longer with ATTRv, which can affect daily life. This month did not establish which treatments work best for specific situations, because the real-world studies were descriptive and the treatment switch data were short-term. The main value right now is a clearer picture of variability, delays, and longer-term complications that research and health systems are still working to address. [3] [4]

This month strengthened the practical evidence that different tests answer different diagnostic and monitoring questions in ATTR. For ATTRv with nerve symptoms, one study found big differences in how often common biopsy sites actually detect amyloid, meaning some negative biopsies may miss the disease. For inherited ATTR more broadly, a new long-read genetic test workflow matched existing methods while potentially returning results sooner. For ATTR cardiomyopathy, continuous heart rhythm monitoring found that rhythm problems are frequent early on and are more likely when amyloid burden and conduction problems are greater. [5] [6] [7]

In symptomatic ATTRv with peripheral neuropathy, nerve biopsy detected amyloid much more often than fat aspirate or skin biopsy in the patients studied. When people had both skin biopsy and fat aspirate, skin biopsy was more likely to detect amyloid than fat aspirate. This helps explain why diagnosis can remain uncertain after a negative biopsy from a less sensitive site, although the study did not address procedure risks or patient experience with each option. [5]

For genetic confirmation of ATTRv, a long-read sequencing approach covering the full TTR gene correctly detected all known disease-causing variants seen in validation samples and matched short-read sequencing results. The report also described shorter turnaround time and lower reagent costs after implementation in routine clinical samples. For patients, the main meaning is that testing technology is moving toward more complete and potentially faster detection of TTR variants, though availability will vary by location. [6]

In newly diagnosed, untreated cardiac amyloidosis, implantable loop recorders found that slow heart rhythms needing a pacemaker-level indication and new atrial fibrillation were common, and both were more frequent in ATTR-CM than in light-chain cardiac amyloidosis. The study also reported that higher measured amyloid burden in the heart and baseline conduction changes were linked to higher risk of these rhythm problems. This adds to the picture that rhythm monitoring can uncover issues that may not be obvious from symptoms alone, even early in the disease course. [7]

For patients and caregivers, these studies mainly add understanding of how ATTR is confirmed and how heart complications can be detected, rather than introducing a new treatment result. The biopsy comparison helps clarify why some tissue tests may miss amyloid more often than others in ATTRv neuropathy, which can affect how confident a diagnosis feels after testing. The genetic testing study suggests that TTR variant testing can be accurate and may become faster in some laboratories over time. The rhythm monitoring study shows that heart rhythm problems can be frequent soon after diagnosis in ATTR-CM and may relate to amyloid amount in the heart, but it does not by itself show which monitoring strategy leads to better outcomes. [5] [6] [7]

This month included early-stage and rare-variant research that helps explain why ATTRv can look so different from one person to another. Reports of unusual TTR gene changes described very early heart involvement and eye findings in specific families, showing how the first signs may appear outside the heart or before standard heart ultrasound changes. Separately, detailed structural work on amyloid from brain tissue showed that the physical shape of TTR amyloid can differ by organ, which may help explain why the brain, eyes, nerves, and heart can be affected in different ways. [8] [9] [10]

In three people (a mother and her two daughters) linked to the Trp61Leu TTR variant, cardiac involvement was described as starting before age 40, and eye (vitreous) amyloid often appeared before the heart disease. The report also described a person who developed ATTR after receiving a liver through a domino transplant, highlighting that the liver can drive ongoing production of amyloid-forming TTR. Because this is a small case-series, it mainly signals what can happen in this specific variant rather than defining what most people with ATTRv will experience. [8]

A separate family-based study identified a new G47R TTR mutation in a woman with early-onset ATTR cardiomyopathy and showed in laboratory tests that this variant destabilizes TTR and promotes amyloid formation. In test-tube experiments, tafamidis (a TTR stabilizer) suppressed amyloid formation for this variant, and blood measurements suggested low TTR tetramer levels in affected and carrier family members that improved with tafamidis in the proband. This kind of work helps connect a specific genetic change to a biological mechanism, but it does not tell how often the variant occurs or how it behaves across many unrelated patients. [9]

Looking at ATTR amyloid in human brain tissue, cryo-electron microscopy showed that fibrils from V30M and V30G cases had folds that differed from those previously reported in peripheral tissues and in the eye. Even with this diversity, the researchers also identified conserved regions shared across fibrils, including a segment already being explored for diagnostic and therapy development. For patients, the main meaning is that organ-specific biology may contribute to why symptoms and treatment responses can vary across tissues. [10]

For patients, these studies are most relevant when there is a rare family variant, unusually early symptoms, or organ involvement such as eye or brain problems. The case and family reports help clarify that some variants may show eye signs early and may affect the heart before standard imaging looks abnormal, but this information is based on very small numbers. The structural brain study does not change diagnosis or treatment today, but it supports a clearer picture that ATTR amyloid is not identical in every organ, which could matter for future tests and therapies designed for specific tissues. Many details, including how common these variants are and how generalizable the patterns are, remain uncertain. [8] [9] [10]